BridgeBio Pharma (NASDAQ:BBIO) Director Andrea Ellis Sells 64,921 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Andrea Ellis sold 64,921 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $64.87, for a total transaction of $4,211,425.27. Following the completion of the sale, the director directly owned 18,589 shares in the company, valued at approximately $1,205,868.43. The trade was a 77.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

BridgeBio Pharma Stock Down 1.2%

BBIO traded down $0.81 during midday trading on Friday, reaching $65.36. 3,243,909 shares of the company’s stock were exchanged, compared to its average volume of 3,213,834. The business has a 50-day simple moving average of $73.85 and a two-hundred day simple moving average of $65.11. The firm has a market capitalization of $12.67 billion, a price-to-earnings ratio of -17.29 and a beta of 1.13. BridgeBio Pharma, Inc. has a one year low of $28.33 and a one year high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last posted its earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The company had revenue of $154.18 million during the quarter, compared to analyst estimates of $150.71 million. During the same period in the previous year, the business earned ($1.40) EPS. BridgeBio Pharma’s revenue for the quarter was up 2521.2% compared to the same quarter last year. As a group, research analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of BridgeBio Pharma in a report on Wednesday, January 21st. TD Cowen reiterated a “buy” rating on shares of BridgeBio Pharma in a research note on Monday, January 12th. Leerink Partners lifted their price objective on BridgeBio Pharma from $75.00 to $86.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Truist Financial boosted their price objective on BridgeBio Pharma from $86.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Finally, HC Wainwright raised their target price on BridgeBio Pharma from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Twenty-two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $82.50.

Institutional Trading of BridgeBio Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in BridgeBio Pharma during the 2nd quarter worth approximately $25,000. Aster Capital Management DIFC Ltd acquired a new position in shares of BridgeBio Pharma in the third quarter valued at approximately $31,000. Harvest Fund Management Co. Ltd bought a new stake in shares of BridgeBio Pharma during the third quarter worth $34,000. Jones Financial Companies Lllp acquired a new stake in shares of BridgeBio Pharma during the first quarter worth $35,000. Finally, First Horizon Corp acquired a new stake in shares of BridgeBio Pharma during the third quarter worth $36,000. 99.85% of the stock is owned by institutional investors.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.